Reuters Health regulators granted a priority review for Bayer's colorectal cancer drug regorafenib, potentially speeding up the experimental treatment's route to market. The Food and Drug Administration grants priority reviews to medicines that are considered potentially significant therapeutic...
FULL ARTICLE AT Fox News